Exchange: NASDAQ·Updated 04:37 PM EST
ALLO logo

ALLO Allogene Therapeutics Inc

$0.64
$0.0392
(5.88%)
Today
Closed $0.6277
$0.0123
(1.96%)
After Hours
Reported EarningsNov 5
Mkt Cap$231.06M
Vol7.57M

About ALLO

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
51

Neutral Sentiment

How do you feel about ALLO?

Expharmaguy
The share price is dropping but there is no evidence that the stock is failing because of a fundamental change in the the Alpha 3 or ALLO-329 story. In fact, the opposite is true. Alpha 3 remains on track; the futility analysis was good enough for FDA to grant RMAT & fast track designations; the company ended 3Q w 389 M in cash, and enrollment momentum is continuing. So the conclusion is that the price is dropping because the major inflection points are 6-18 months away. For long term investors that means a buying opportunity. I continue to accumulate. Opinion only not advice. $ALLO
9
Gurujoe
$ALLO | ACR 2026 — Potential Platform-Defining Data and a Significant Re-Rating Opportunity Today’s ALLO-329 Phase 1 RESOLUTION results are exceptionally encouraging, particularly given the early dose levels and reduced conditioning regimens. Key highlights: * 8/10 scleroderma patients achieved and maintained clinically meaningful improvements in modified Rodnan Skin Score (mRSS). * 9/10 patients remained off background immunosuppressive therapy. * Clinical activity was observed across all three conditioning approaches, including NO lymphodepletion. * Favorable initial safety in 18 patients: no DLTs, ICANS, GvHD, IEC-HS or Grade ≥3 CRS. * Durable clinical improvement occurred without complete peripheral B-cell depletion, suggesting a potentially differentiated immune-reset mechanism. The real breakthrough could be Dagger®. If ALLO-329 can deliver durable efficacy without conventional lymphodepleting chemotherapy, it could fundamentally change the safety, accessibility, cost structure and commercial potential of autoimmune CAR-T therapy. Importantly, Dagger is a modular platform, with potential applications extending beyond scleroderma, lupus and myositis into additional autoimmune diseases and oncology. Recent SITC preclinical findings further support its adaptability. Valuation disconnect: With approximately $389M in cash at Q3 and runway into 2029, ALLO’s current valuation appears to assign limited value to the potential of its autoimmune franchise, Dagger platform and advancing oncology pipeline. The dataset remains small and early, and durability requires further validation. Nevertheless, these results provide compelling initial evidence of clinical activity with reduced conditioning. My view: ALLO has delivered an important early proof-of-concept. If replicated in larger cohorts with sustained responses, this could support a substantial re-rating and potentially position ALLO-329 among the most differentiated autoimmune CAR-T therapies in development. Bullish. Long $ALLO.
8
BraSJ
$ALLO this have to happen, it will put pressure on board to come with news "great or not" I’m not going anywhere, I’ll buy more bring average down much as I can. gL all hang tie
5
Hal2026
$ALLO ALPHA3 and RESOLUTION Q3 Update This infographic focuses exclusively on the two most important programs discussed during Allogene's Q3 call: ALPHA3 and RESOLUTION. Pay particular attention to Roberts' description of a "virtuous cycle" in RESOLUTION. This is important. Early enrollment of dcSSc patients was followed by growing enthusiasm among SSc investigators, which in turn drove additional SSc enrollment. We saw this first hand with Johns Hopkins, and I made note of it many times for all of you to witness. That is what a virtuous cycle means: a positive, self-reinforcing process where each development strengthens the next. Understanding why this happened is particularly interesting heading into Monday's expanded clinical readout.
7
Hal2026
$ALLO There is a big difference between a biotech saying it believes in its technology and continuing to invest in developing an entire pipeline around it. Look at the chronology. Dagger emerged from ALLO-316, followed by ALLO-329 and the RESOLUTION trial, then BCMA/CD70, and now DLL3/CD70. Allogene has been accumulating clinical and translational data while continuing to expand its Dagger-based pipeline. Why would a company with access to its own data keep investing in new assets built around technology that was showing no evidence of working?
7
Hal2026
$ALLO Let's not forget. The Alpha3 Interim EFS Analysis is approaching in June of 2027. There is a high probability Allogene will submit an early BLA in 2027 for Cema-cel based on the Interim EFS results, just like TRANSFORM did. Allogene has already turned manufacturing back on for production readiness, which is required for an early BLA submission.
6
Gurujoe
$ALLO | Monday’s ACR Data Could Be a Major Clinical AND Platform Inflection Point Following today’s Q3 conference call, I’m increasingly bullish on Monday’s expanded ALLO-329 autoimmune CAR-T presentation. Management’s confidence and unusually specific guidance were particularly encouraging. Several important signals from the call: 1. Clinically meaningful scleroderma efficacy: Management explicitly identified an approximately 5-point reduction in the modified Rodnan Skin Score (mRSS) as a widely accepted threshold for clinically meaningful improvement in systemic sclerosis. Importantly, management emphasized that this is an established clinical benchmark, not an arbitrary company-defined measure. This was a notable comment ahead of Monday’s efficacy disclosure. 2. Management’s enthusiasm for systemic sclerosis: Investigators treating diffuse cutaneous systemic sclerosis have demonstrated particularly strong engagement. Management highlighted this as the most mature patient subgroup and expressed excitement about presenting its efficacy data. 3. Dagger technology validation: Monday’s dataset includes additional patients, longer follow-up, three dose levels and three conditioning approaches, including NO lymphodepletion. Management specifically encouraged investors to examine whether ALLO-329 delivers on its original promise of meaningful CAR-T activity with reduced or eliminated chemotherapy conditioning. 4. Encouraging early safety: No high-grade toxicities or ICANS reported to date, although the two serious adverse events and their relationship to conditioning require further clarification. 5. Broader oncology implications: Demonstrating efficacy, CAR-T expansion and persistence without lymphodepletion could provide important human proof of concept for Dagger, potentially extending its value beyond autoimmune disease into Allogene’s next-generation oncology programs, including solid tumors. Why Monday could be particularly impactful: Management knows the underlying data and repeatedly expressed confidence in the program. Its specific discussion of the 5-point mRSS benchmark, the mature systemic sclerosis subgroup and conditioning-independent activity provides an encouraging setup. A meaningful proportion of patients achieving sustained ≥5-point mRSS improvement, particularly without lymphodepletion, would be a powerful clinical signal. To be clear, clinical significance is not the same as statistical significance. The actual patient-level changes, sample size, variability and durability will determine how compelling the evidence is. From an investment perspective, successful validation could materially increase ALLO-329’s risk-adjusted NPV while introducing substantial oncology platform optionality. This isn’t simply about validating another autoimmune CAR-T asset. It’s potentially about validating an entirely different, more accessible model for off-the-shelf CAR-T across autoimmune disease and oncology. Monday could be a meaningful re-rating catalyst. Bullish on the setup. Long
6
beachrider
$ALLO green 1.19 feels better than red 1.19 but, cmon 1.19?! This is going to be either legendary or some good character development.
5
gandolf63
$ALLO Allogene Therapeutics is actively developing next-generation allogeneic CAR T-cell (AlloCAR T) therapies designed to reduce or entirely eliminate the need for conventional lymphodepleting chemotherapy. I still say there is a good possibility BIG PHARMA would want that! Stay tuned!
4
Daryl142
$ALLO looking for a 50,000% return to break even, lol! I have faith in my Allo and the researchers!!
4
AS1980
$ALLO volume dried Spread narrower Shorts started covering very very cheaply and slowly They do not have anything to fear until next summer
1
Unburdened
$ALLO Should have sold this dog Sh$& when Chang resigned as CEO and CFO gave notice. Have they found a new CFO yet? What is the delay? No one wants this plum of a job? Can the new CFO, be worse than the one that's leaving? That fool did an offering at two dollars a share when it was trading at four dollars a share. What complete and utter incompetence.
3
dima23113
$ALLO Utterly incompetent fools—they carried out a secondary share offering at $2 a share when the market price was $4.50. The current price is the direct result of the company’s reckless actions. It’s practically fraud.
3
gandolf63
$ALLO I have been buying a little every day it goes down. I think their technology is disruptive
3
Unburdened
$ALLO Another LinkedIn post by #ALLO. I think the rate of posts goes up as the price tag goes down
3
gandolf63
$ALLO The most critical near-term catalyst for Allogene is its expansion autoimmune • ALLO-329 (RESOLUTION Trial Data Update): Allogene is scheduled to release a significant clinical and translational data update in Q4 2026 for its Phase 1 RESOLUTION basket trial. • What it is targeting: This trial evaluates ALLO-329, a next-generation dual-targeted (CD19/CD70) AlloCAR T product for severe autoimmune conditions including Systemic Lupus Erythematosus (SLE), myositis, and scleroderma. • Why it's crucial: The Q4 readout will detail multiple dose levels (including the 20 million and 40 million cell cohorts). It is heavily watched because it utilizes Allogene’s proprietary Dagger® technology, which is designed to selectively eliminate the patient's rejection-primed immune cells. If successful, it could drastically reduce or entirely eliminate the need for harsh chemotherapy-based lymphodepletion before cell infusion, making autoimmune CAR-T vastly safer and easier to tolerate.
3
Portfoliovalue1
$ALLO two promising projects: one of short or medium term growth (alpha3) another one for long term growth (329). Good discount at this price for long term hold.
1
Highbred
$ALLO although more data is needed, safety profile and response rates are excellent. If all indications are fully successful, this would translate to billions in annual sales. However, this would take years and a lot more funding (potentially destroying large holders equity even further). My prediction: cheap buyout sooner than later.....mainly for the dagger technology, with the indications as cherries on top. Cash and CVR's to appease the holdouts. Large holders will go along as they have larger stakes in the bidders stock, and simply view the transaction as an asset transfer from a risky bucket into a vault. Altogether, net cash outlay for bidder will be minimized due to Allo's cash on hand. And in the end, retail will not get the fantasized huge payoff, as is in line with historical data surrounding bio stocks overall.
2
Filvul
$ALLO maybe their next medicine-changing, history-making pivotal trial will develop a stock price that can go even sub-zero..
2
beachrider
$ALLO at risk for under 1.00 rule on Nasdaq and after 30 days company has 180 days to "fix it" puts Allo under pressure for a reverse split.
2

Advertisement|Remove ads.